These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 35180847)

  • 1. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
    Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
    BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.
    Keane F; Chou JF; Walch H; Schoenfeld J; Singhal A; Cowzer D; Harrold E; O'Connor CA; Park W; Varghese A; El Dika I; Balogun F; Yu KH; Capanu M; Schultz N; Yaeger R; O'Reilly EM
    J Natl Cancer Inst; 2024 Sep; 116(9):1429-1438. PubMed ID: 38702822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic ductal adenocarcinomas from Mexican patients present a distinct genomic mutational pattern.
    Sanchez P; Espinosa M; Maldonado V; Barquera R; Belem-Gabiño N; Torres J; Cravioto A; Melendez-Zajgla J
    Mol Biol Rep; 2020 Jul; 47(7):5175-5184. PubMed ID: 32583281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Effect of Driver Mutations of
    Gu Y; Ji Y; Jiang H; Qiu G
    Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
    Sun H; Zhang B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
    Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
    Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.
    Schlitter AM; Segler A; Steiger K; Michalski CW; Jäger C; Konukiewitz B; Pfarr N; Endris V; Bettstetter M; Kong B; Regel I; Kleeff J; Klöppel G; Esposito I
    Sci Rep; 2017 Feb; 7():41064. PubMed ID: 28145465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
    Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
    Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience.
    Kimura R; Ohtsuka T; Kubo M; Kajihara A; Fujii A; Watanabe Y; Mori Y; Ikenaga N; Nakata K; Shindo K; Ohuchida K; Nakamura M
    Surg Today; 2021 Apr; 51(4):619-626. PubMed ID: 32885350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
    Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
    Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
    Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
    [No Abstract]   [Full Text] [Related]  

  • 15. Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value.
    Kwon MJ; Jeon JY; Park HR; Nam ES; Cho SJ; Shin HS; Kwon JH; Kim JS; Han B; Kim DH; Choi YL
    Pancreas; 2015 Apr; 44(3):484-92. PubMed ID: 25513781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.
    Yachida S; White CM; Naito Y; Zhong Y; Brosnan JA; Macgregor-Das AM; Morgan RA; Saunders T; Laheru DA; Herman JM; Hruban RH; Klein AP; Jones S; Velculescu V; Wolfgang CL; Iacobuzio-Donahue CA
    Clin Cancer Res; 2012 Nov; 18(22):6339-47. PubMed ID: 22991414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
    Voutsadakis IA; Digklia A
    Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Will molecular diagnostics become established in pancreatic pathology?].
    Sipos B; Sperveslage J
    Pathologe; 2013 Nov; 34 Suppl 2():214-20. PubMed ID: 24196616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
    Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
    Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.